1170P Pembrolizumab (Pembro) + concurrent chemoradiotherapy (CCRT) for high-risk locally advanced cervical cancer (LACC): Post hoc subgroup analyses from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Vladyslav Sukhin, Tomoka Usami, Júlia Vízkeleti, Hong Zhu, Pierre Elias, Jonathan Lopez, Andrés Acevedo, Ritu Salani, F.J.S. Melo Cruz, В. В. Саевец, Ayman Salhab, Bahriye Aktas, Flora Zagouri, June‐Yong Lee, V. Samouëlian, Pan Liu, K.U. Yamada, S. Toker, D. Lorusso
IF 65.4 (2025) Annals of Oncology
키워드
PembrolizumabChemoradiotherapyCervical cancerPhases of clinical researchPost-hoc analysisPost hoc